Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results

CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park

The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4

Bayer expands MRXperion power injector capabilities with FDA nod

The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma

Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline

Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss

Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy

SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum

AbbVie’s Risankizumab shows strong results in hard-to-treat Crohn’s disease patients

This study evaluated a difficult-to-treat Crohn's disease patient population